Literature DB >> 17709369

P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution.

Naveed Shaik1, Nagdeep Giri, Guoyu Pan, William F Elmquist.   

Abstract

P-glycoprotein (P-gp)-mediated efflux at the blood-brain barrier has been implicated in limiting the brain distribution of many anti-HIV1 drugs, primarily protease inhibitors, resulting in suboptimal concentrations in this important sanctuary site. The objective of this study was to characterize the interaction of abacavir with P-gp and determine whether P-gp is an important mechanism in limiting abacavir delivery to the central nervous system (CNS). In vitro and in vivo techniques were employed to characterize this interaction. Abacavir stimulated P-gp ATPase activity at high concentrations. The cellular accumulation of abacavir was significantly decreased by approximately 70% in Madin-Darby canine kidney II (MDCKII)-MDR1 monolayers compared with wild-type cells and was completely restored by the P-gp inhibitors ((R)-4-((1aR,6R,10bS)-1,2-difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride) (LY335979) and N-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]-5-methoxy-9-oxo-10H-acridine-4-carboxamide (GF120918). Directional flux experiments indicated that abacavir had greater permeability in the basolateral-to-apical direction (1.58E-05 cm/s) than in the apical-to-basolateral direction (3.44E-06 cm/s) in MDR1-transfected monolayers. The directionality in net flux was abolished by both LY335979 and GF120918. In vivo brain distribution studies showed that the AUC(plasma) in mdr1a(-/-) CF-1 mutant mice was approximately 2-fold greater than the AUC(plasma) in the wild type, whereas the AUC(brain) in the mutant was 20-fold higher than that in the wild type. Therefore, the CNS drug targeting index, defined as the ratio of AUC brain-to-plasma for mutant over wild type, was greater than 10. These data are the first in vitro and in vivo evidence that a nucleoside reverse transcriptase inhibitor is a P-gp substrate. The remarkable increase in abacavir brain distribution in P-gp-deficient mutant mice over wild-type mice suggests that P-gp may play a significant role in restricting the abacavir distribution to the CNS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17709369     DOI: 10.1124/dmd.107.017723

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  30 in total

Review 1.  Advances in predictive in vitro models of drug-induced nephrotoxicity.

Authors:  Joanne Y-C Soo; Jitske Jansen; Rosalinde Masereeuw; Melissa H Little
Journal:  Nat Rev Nephrol       Date:  2018-06       Impact factor: 28.314

2.  HIV-1 Tat and opioids act independently to limit antiretroviral brain concentrations and reduce blood-brain barrier integrity.

Authors:  Crystal R Leibrand; Jason J Paris; Austin M Jones; Quamrun N Masuda; Matthew S Halquist; Woong-Ki Kim; Pamela E Knapp; Angela D M Kashuba; Kurt F Hauser; MaryPeace McRae
Journal:  J Neurovirol       Date:  2019-05-17       Impact factor: 2.643

Review 3.  Pharmacokinetic and pharmacodynamic drug interactions between antiretrovirals and oral contraceptives.

Authors:  Victoria Tittle; Lauren Bull; Marta Boffito; Nneka Nwokolo
Journal:  Clin Pharmacokinet       Date:  2015-01       Impact factor: 6.447

Review 4.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

5.  Toward eradicating HIV reservoirs in the brain: inhibiting P-glycoprotein at the blood-brain barrier with prodrug abacavir dimers.

Authors:  Hilda A Namanja; Dana Emmert; David A Davis; Christopher Campos; David S Miller; Christine A Hrycyna; Jean Chmielewski
Journal:  J Am Chem Soc       Date:  2011-09-09       Impact factor: 15.419

6.  The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes.

Authors:  Omar Janneh; Andrew Owen; Patrick G Bray; David J Back; Munir Pirmohamed
Journal:  Br J Pharmacol       Date:  2009-12-10       Impact factor: 8.739

7.  Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors.

Authors:  Todd Hulgan; John P Donahue; Laura Smeaton; Minya Pu; Hongying Wang; Michael M Lederman; Kimberly Smith; Hernan Valdez; Christopher Pilcher; David W Haas
Journal:  Eur J Clin Pharmacol       Date:  2009-11       Impact factor: 2.953

8.  Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design.

Authors:  Nagdeep Giri; Sagar Agarwal; Naveed Shaik; Guoyu Pan; Ying Chen; William F Elmquist
Journal:  Drug Metab Dispos       Date:  2008-12-04       Impact factor: 3.922

Review 9.  Methadone, buprenorphine, and street drug interactions with antiretroviral medications.

Authors:  Valerie A Gruber; Elinore F McCance-Katz
Journal:  Curr HIV/AIDS Rep       Date:  2010-08       Impact factor: 5.071

10.  Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies.

Authors:  Naveed Shaik; Nagdeep Giri; William F Elmquist
Journal:  J Pharm Sci       Date:  2009-11       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.